<DOC>
	<DOCNO>NCT02235402</DOCNO>
	<brief_summary>The aim study compare effect lacidipine marker platelet activation rheological factor hypertensive patient bendrofluazide</brief_summary>
	<brief_title>A Randomised , Parallel-group , Double-blind , Double-dummy Study Compare Effects Lacidipine Versus Bendrofluazide Markers Platelet Activation Haemorheological Factors Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Lacidipine</mesh_term>
	<mesh_term>Bendroflumethiazide</mesh_term>
	<criteria>Age 18 Hypertensive screening : Diastolic blood pressure ( DBP ) 95 115 mm Hg / systolic blood pressure ( SBP ) &gt; = 160 mm Hg therapy monotherapy . If currently monotherapy , DBP could &lt; 95 mm Hg SBP &lt; 160 mm Hg , patient must experience unacceptable side effect current treatment . Patient must able stop treatment placebo run phase four week without endanger health ( investigator 's discretion ) Hypertensive randomisation : DBP 95115 mm Hg SBP &gt; =160 Able give write informed consent Grad III grad IV hypertensive retinopathy Renal impairment ; serum creatinine &gt; 150 Âµmol/L Heart failure . ( New York Heart Association ( NYHA ) Class III IV ) Liver impairment ( abnormal Liver function test ( LFT ) aspartateamino transferase ( AST ) / alanineamino transferase ( ALT ) &gt; 2x upper normal limit bilirubin &gt; 2x upper normal limit ) Recent ( &lt; 2 month ) history unstable angina Recent ( &lt; 2 month ) history myocardial infarction Recent ( &lt; 2 month ) history stroke History diabetes mellitus impaired glucose tolerance random blood glucose &gt; = 9 mMol/L Any acute systemic illness infection Any severe disease could interfere survival wellbeing study ( e.g . malignancy ) Patients child bear potential Current previous drug / alcohol abuse Severely limit venous access Haemoglobin &lt; 10g/dL ( male patient ) , haemoglobin &lt; 9g/dL ( female patient ) Requirement anticoagulant therapy Severe valvular heart disease ( investigator 's discretion ) Atrial fibrillation serious cardiac dysrhythmia History thyroid disease abnormal thyroid function test ( thyroid stimulate hormone ( TSH ) &lt; 0.4 mU/L &gt; 5.4 mU/L ) History connective tissue disorder Concurrent participation clinical trial participation within two month enrolment Requirement restrict drug Patients currently treatment lacidipine bendrofluazide ( BNFZ ) Patients unable attend clinic Any clinical condition opinion investigator , would preclude safe fulfillment protocol safe administration trial medication Seated blood pressure ( BP ) exceed either 210 mm Hg ( systolic ) 115 mm Hg ( diastolic ) screen randomization Standing BP &lt; 140 mm Hg ( systolic ) &lt; 95 mm Hg ( diastolic ) randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>